HEDIS Results

Medicaid HEDIS® Annual Rates.

Molina’s scores are below. You can see how Molina performs compared to our target goal.

Measure / Data Element

2020

2021

2021 Goal

Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA)

53.21%

59.25%

67.60%

Annual Dental Visits (ADV) Total

59.62%

48.14%

50.00%

Antidepressant Medication Management (AMM) Effective Continuation Phase Treatment

66.27%

58.89%

42.90%

Appropriate Testing for Pharyngitis (CWP)

72.75%

75.29%

80.70%

Appropriate Treatment for Upper Respiratory Infection (URI)

71.40%

74.74%

90.80%

Asthma Medication Ratio (AMR) Total

NA

62.89%

68.40%

Avoidance of Antibiotic Treatment for Acute Bronchitis / Bronchiolitis (AAB) Total

44.87%

55.84%

59.50%

Breast Cancer Screening (BCS)

NA

36.36%

56.70%

Cervical Cancer Screening (CCS)

45.26%

47.93%

62.00%

Childhood Immunization Status (CIS) Combination #10

NA

17.27%

42.30%

Chlamydia Screening in Women (CHL) Total

53.91%

53.13%

60.10%

Comprehensive Diabetes Care (CDC) BP Control < 140/90

55.43%

51.82%

63.20%

Comprehensive Diabetes Care (CDC) HbA1c Control < 8.0%

36.05%

36.25%

49.60%

Comprehensive Diabetes Care (CDC) Eye Exam

53.88%

49.15%

55.80%

Controlling High Blood Pressure (CBP)

46.72%

47.20%

60.00%

Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)

77.90%

71.19%

78.90%

Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (FUA) 7-Day Follow-Up Total

2.56%

2.73%

16.30%

Follow-Up After Emergency Department Visit for Mental Illness (FUM) 7-Day Follow-Up Total

17.26%

18.75%

45.40%

Follow-Up After Hospitalization for Mental Illness (FUH) 7-Day Follow-Up Total

25.95%

29.44%

44.80%

Follow-Up for Children Prescribed ADHD Medication (ADD)Continuation and Maintenance Phase

NA

60.66%

60.30%

Immunizations for Adolescents (IMA) Combination #2

14.38%

10.22%

41.80%

Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (IET) Engagement of AOD Treatment Total

7.04%

7.05%

16.50%

Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) Total

25.00%

16.49%

34.80%

Pharmacotherapy Management of COPD Exacerbation (PCE) Systemic Corticosteroids

60.00%

54.39%

73.60%

Pharmacotherapy Management of COPD Exacerbation (PCE) Bronchodilator

77.65%

80.70%

86.90%

Prenatal and Postpartum Care (PPC) Timeliness of Prenatal Care

99.03%

95.38%

88.30%

Prenatal and Postpartum Care (PPC) Postpartum Care

69.34%

66.42%

78.30%

Risk of Continued Opioid Use (COU) 31-Day Total

2.98%

4.43%

≤ 2.80%

Statin Therapy for Patients with Cardiovascular Disease (SPC) Received Statin Therapy Total

NA

78.95%

81.90%

Statin Therapy for Patients with Cardiovascular Disease (SPC) Statin Adherence 80% Total

NA

86.67%

74.90%

Statin Therapy for Patients with Diabetes (SPD) Received Statin Therapy

NA

52.14%

68.50%

Statin Therapy for Patients with Diabetes (SPD) Statin Adherence 80%

NA

77.05%

71.90%

Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP) Total

62.41%

57.02%

66.40%

Use of Imaging Studies for Low Back Pain (LBP)

81.02%

71.96%

77.80%

Use of Opioids at High Dosage (HDO)

BR

4.76%

≤ 2.90%

Use of Opioids from Multiple Providers (UOP) Multiple Prescribers and Multiple Pharmacies

BR

2.80%

≤ 1.30%

Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC) BMI Percentile

57.91%

49.15%

80.60%

 

NA = Not Available Due to Small Denominator
NB = No Benefit
NR = Not Reported
NQ = Not Required
BR = Biased Rate